HUP0302053A2 - o-Acetil-szalicilsav bázikus aminosavakkal alkotott stabil sói - Google Patents

o-Acetil-szalicilsav bázikus aminosavakkal alkotott stabil sói

Info

Publication number
HUP0302053A2
HUP0302053A2 HU0302053A HUP0302053A HUP0302053A2 HU P0302053 A2 HUP0302053 A2 HU P0302053A2 HU 0302053 A HU0302053 A HU 0302053A HU P0302053 A HUP0302053 A HU P0302053A HU P0302053 A2 HUP0302053 A2 HU P0302053A2
Authority
HU
Hungary
Prior art keywords
amino acids
basic amino
acetylsalicylic
stable salts
particle size
Prior art date
Application number
HU0302053A
Other languages
English (en)
Inventor
Hubert Appolt
Gerhard Franckowiak
Wolfram Ledwoch
Gregor Leifker
Hans-Peter Wirges
Original Assignee
Bayer Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag. filed Critical Bayer Ag.
Publication of HUP0302053A2 publication Critical patent/HUP0302053A2/hu
Publication of HUP0302053A3 publication Critical patent/HUP0302053A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

A találmány o-acetil-szalicilsav bázikus aminosavakkal alkotott stabilsóira, előállításukra alkalmas eljárásra, valamint gyógyszerkéntialkalmazásukra vonatkozik. A bázikus aminosavval alkotott o-acetil-szalicilátokra jellemző, hogy - Malvern 2600D-készülékkelszabványfeltételek mellett mért szemcseméreteloszlásuk szerint - 160mm feletti átlagos szemcseméretével és 60%-nál több 100-200 mm közöttiszemcseméretű részecskével rendelkeznek. Ó
HU0302053A 2000-07-18 2001-07-05 Stable salts of o-acetylsalicylic with basic amino acids amino acids HUP0302053A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10034802A DE10034802A1 (de) 2000-07-18 2000-07-18 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
PCT/EP2001/007669 WO2002005782A2 (de) 2000-07-18 2001-07-05 Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren

Publications (2)

Publication Number Publication Date
HUP0302053A2 true HUP0302053A2 (hu) 2003-09-29
HUP0302053A3 HUP0302053A3 (en) 2010-03-29

Family

ID=7649258

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302053A HUP0302053A3 (en) 2000-07-18 2001-07-05 Stable salts of o-acetylsalicylic with basic amino acids amino acids

Country Status (34)

Country Link
US (2) US6773724B2 (hu)
EP (1) EP1365737B1 (hu)
JP (2) JP2004507463A (hu)
KR (1) KR100773658B1 (hu)
CN (1) CN1205176C (hu)
AR (1) AR030305A1 (hu)
AT (1) ATE293589T1 (hu)
AU (2) AU2001278471B2 (hu)
BR (1) BR0112538A (hu)
CA (1) CA2416288C (hu)
CR (1) CR6888A (hu)
CZ (1) CZ300337B6 (hu)
DE (2) DE10034802A1 (hu)
DK (1) DK1365737T3 (hu)
EC (1) ECSP034437A (hu)
ES (1) ES2241849T3 (hu)
GT (1) GT200100134A (hu)
HK (1) HK1061811A1 (hu)
HR (1) HRP20030108B1 (hu)
HU (1) HUP0302053A3 (hu)
IL (2) IL153873A0 (hu)
MX (1) MXPA03000510A (hu)
MY (1) MY134521A (hu)
NO (1) NO20030222D0 (hu)
PE (1) PE20020267A1 (hu)
PL (1) PL204593B1 (hu)
PT (1) PT1365737E (hu)
RS (1) RS50329B (hu)
SK (1) SK286162B6 (hu)
SV (1) SV2002000557A (hu)
TW (1) TWI299729B (hu)
UY (1) UY26841A1 (hu)
WO (1) WO2002005782A2 (hu)
ZA (1) ZA200300469B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE10202019A1 (de) * 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
US8142810B2 (en) 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
ATE442352T1 (de) * 2003-05-16 2009-09-15 Cephalon France Verfahren zur herstellung von modafinil
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20060166901A1 (en) * 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
AU2006346195B2 (en) 2006-07-09 2013-03-07 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
KR101853971B1 (ko) 2007-06-04 2018-05-02 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
CN101314029B (zh) * 2008-06-18 2010-12-08 四川省农业科学院实验场 乙酰水杨酸肽及其制备方法
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
CA2745206C (en) 2008-12-04 2018-09-18 Chongxi Yu High penetration compositions and their applications
CN102803199B (zh) * 2009-06-25 2015-04-15 泰特拉有限公司 乙酰水杨酸盐
CN101633624B (zh) * 2009-08-04 2013-05-01 蚌埠丰原医药科技发展有限公司 改进的赖氨匹林的制备方法
FR2950625B1 (fr) * 2009-09-30 2016-12-02 Holis Tech Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue
FR2965261B1 (fr) * 2009-09-30 2012-10-26 Holis Technologies Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue par ce procede
FR2973370B1 (fr) * 2011-03-29 2013-05-03 Holis Technologies Procede a faible cout pour la preparation d'un acide o-acetylsalicyclique et d'un acide amine basique
CN102503845A (zh) * 2011-09-28 2012-06-20 广州普星药业有限公司 一种dl-赖氨酸阿司匹林盐的制备方法及其应用
IN2014KN02583A (hu) 2012-05-16 2015-05-08 Techfields Pharma Co Ltd
CN102976962B (zh) * 2012-11-20 2015-02-04 南京工业大学 L-鸟氨酸阿司匹林复盐及其制备方法和应用
FR3021654B1 (fr) * 2014-05-28 2016-06-24 Unither Pharmaceuticals Procede de preparation d'un sel d'acide acetylsalicylique et d'un acide amine basique
JP7012725B2 (ja) * 2016-12-23 2022-01-28 アスピエアー ゲーエムベーハー アセチルサリチル酸リジン・グリシン粒子の改良された合成
CA3064012A1 (en) 2017-05-30 2018-12-06 Rhoshan Pharmaceuticals, Inc. In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)
KR20200035047A (ko) * 2017-08-03 2020-04-01 산텐 세이야꾸 가부시키가이샤 클로르헥시딘을 함유하는 의약 조성물
CN113105326A (zh) * 2021-03-24 2021-07-13 海南卓华制药有限公司 赖氨匹林的制备方法及应用
CN114478287A (zh) * 2021-12-31 2022-05-13 蚌埠丰原医药科技发展有限公司 一种赖氨匹林晶型及制备方法和应用
CA3239851A1 (en) 2022-01-05 2023-07-13 Karlheinz Nocker Improved synthesis of lysine acetylsalicylate · glycine particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2115060A1 (en) * 1970-11-26 1972-07-07 Metabio Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin
ES388158A1 (es) * 1971-02-11 1974-03-16 Liade Sa Lab Procedimiento de obtencion de sales solubles del acido ace-til salicilico.
JPS4856815A (hu) * 1971-11-13 1973-08-09
JPS55127345A (en) * 1979-03-23 1980-10-02 Kyowa Hakko Kogyo Co Ltd Preparation of acetylsalicylic acid salt
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
JPS56113741A (en) * 1980-02-13 1981-09-07 Mitsui Toatsu Chem Inc Preparation of crystal of acetylsalicylic acid salt
JPS5721345A (en) * 1980-07-15 1982-02-04 Mitsui Toatsu Chem Inc Purification of acetylsalicylate salt
CS247688B1 (cs) * 1984-12-22 1987-01-15 Evzen Kasafirek Způsob výroby soli lysinu s kyselinou acetylsalicylovou
JPS632929A (ja) * 1986-06-20 1988-01-07 Kao Corp アセチルサリチル酸製剤
EP0499142A3 (en) * 1991-02-09 1993-05-05 Hoechst Aktiengesellschaft Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs
DE4332093C2 (de) * 1993-09-22 1995-07-13 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
KR20030019586A (ko) 2003-03-06
EP1365737B1 (de) 2005-04-20
YU2003A (sh) 2006-08-17
NO20030222L (no) 2003-01-16
US20050009791A1 (en) 2005-01-13
PT1365737E (pt) 2005-08-31
PL365648A1 (en) 2005-01-10
PE20020267A1 (es) 2002-06-08
HUP0302053A3 (en) 2010-03-29
SK672003A3 (en) 2003-06-03
ECSP034437A (es) 2003-03-31
HRP20030108B1 (en) 2006-12-31
AR030305A1 (es) 2003-08-20
GT200100134A (es) 2002-03-22
BR0112538A (pt) 2003-09-09
US20020091108A1 (en) 2002-07-11
AU2001278471B2 (en) 2004-07-22
CR6888A (es) 2004-10-28
WO2002005782A3 (de) 2003-10-02
MXPA03000510A (es) 2004-04-20
IL153873A0 (en) 2003-07-31
EP1365737A2 (de) 2003-12-03
WO2002005782A2 (de) 2002-01-24
JP2012131824A (ja) 2012-07-12
ZA200300469B (en) 2004-06-21
CA2416288A1 (en) 2003-01-15
CN1205176C (zh) 2005-06-08
ATE293589T1 (de) 2005-05-15
CA2416288C (en) 2009-12-22
HK1061811A1 (en) 2004-10-08
KR100773658B1 (ko) 2007-11-05
US6773724B2 (en) 2004-08-10
HRP20030108A2 (en) 2005-02-28
IL153873A (en) 2009-05-04
NO20030222D0 (no) 2003-01-16
DE50105985D1 (de) 2005-05-25
US7449198B2 (en) 2008-11-11
MY134521A (en) 2007-12-31
UY26841A1 (es) 2002-02-28
DK1365737T3 (da) 2005-07-11
SV2002000557A (es) 2002-10-24
TWI299729B (en) 2008-08-11
CZ2003164A3 (cs) 2003-04-16
ES2241849T3 (es) 2005-11-01
SK286162B6 (sk) 2008-04-07
RS50329B (sr) 2009-09-08
CZ300337B6 (cs) 2009-04-22
PL204593B1 (pl) 2010-01-29
JP2004507463A (ja) 2004-03-11
CN1468209A (zh) 2004-01-14
AU7847101A (en) 2002-01-30
DE10034802A1 (de) 2002-01-31

Similar Documents

Publication Publication Date Title
HUP0302053A2 (hu) o-Acetil-szalicilsav bázikus aminosavakkal alkotott stabil sói
TWI355280B (en) Oral care product and methods of use and manufactu
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
MY151458A (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
HK1068782A1 (en) Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid
YU57599A (sh) Primena derivata fumarne kiseline
HUP0400992A3 (en) Carboxylic acid substituted oxazole derivatives, process for their preparation and their use as ppar-alpha and-gamma activators for the manufacture of pharmaceutical compositions in the treatment of diabetes
HUP0401250A2 (hu) Aeroszol formájú gyógyászati készítmények és eljárás az előállításukra
HUP0401647A2 (hu) Új béta-fenil-alfa-oxi-propionsav-származékok, előállítási eljárásaik és gyógyszerészetileg fontos vegyületek előállításánál történő felhasználásuk
MXPA03001654A (es) Proceso para la elaboracion del acido n-aril-antranilico y sus derivados.
CA2706355A1 (en) Oral care product and methods of use and manufacture thereof
HUP0203204A2 (hu) Orális adagolási forma
AR038298A1 (es) Sales estables del acido o-acetilsalicilico con aminoacidos basicos i i
ITPD20020097A1 (it) Prodotto microincapsulato per l'alimentazione animale a base del salesodico dell'acido n-butirrico e suo sistema di produzione
Piper et al. Humic acid nitrogen
PL365213A1 (en) Enteric ketoacid salts and amino acids
BRPI0408270A (pt) composição farmacêutica compreendendo ácido 5-metil-2-(2'cloro-6'-fluoroanilino)fenilacético
HUP0401234A2 (hu) Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására
WO2004047718A3 (en) Process for manufacturing sustained release microbeads containing venlafaxine hci
NO20033705L (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr
PL377706A1 (pl) Kompozycja farmaceutyczna zawierająca kwas alendronowy, jego sole lub estry oraz sposób jej otrzymywania
EP1896392A4 (en) [(E) -2- [5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL] -1-PROPENYL] BENZOIC ACID ANALOGUES AND PROCESS FOR PRODUCING THE SAME USE OF THESE
HUP0301559A2 (hu) D-pantoténsavat és/vagy annak sóit tartalmazó önthető táplálék- adalékanyagok, és eljárás azok előállítására
WO2000073274A3 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung als adenosinaufnahme-inhibitoren
ATE314094T1 (de) Ein komplex aus alpha-fetoprotein (afp) und einem polyungesättigten fettsäurederivat zur behandlung von immunschwäche

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE

FD9A Lapse of provisional protection due to non-payment of fees